- Email: [email protected]
4859587 Recombinant herpes simplex viruses, vaccines and methods
N e w Patents
sequences either directly or as a fusion protein with the product of a procaryotic gene. The resulting expression product is then either a fusion protein comprising two or more antigenic materials or a fusion protein comprising a part of a procaryotic protein and two or more antigenic materials. These fusion products are capable of eliciting the formation of multivalent antibodies which are cross-reactive with any and all of the native antigenic material. A vaccine is also described utilizing these fusion products.
4859583 CHEMILUMINESCENT IMMUNOCHEMICAL TECHNIQUE FOR LOW MOLECULAR WEIGHT ANTIGENS Michael Heller, Larry Morrison assigned to Amoco Corporation A sample device and method for assaying samples containing members of immunological pairs by chemiluminescence include a first chamber wherein antibody-conjugated reagent antigen labelled with a chemiluminescence moiety is displaced from the antibody by sample antigen. The labelled reagent antigen diffuses into a second chamber, wherein the chemiluminescence moiety reacts with cofactors to produce a light emission proportional to the amount of sample antigen present.
4859587 RECOMBINANT HERPES SIMPLEX VIRUSES, VACCINES AND METHODS Bernard Roizman assigned to Institut Merieux Recombinant herpes viruses useful as effective ingredients in vaccines against both virulent HSV-I and HSV-2 are disclosed. Methods of preparing the recombinant viruses, vaccines incorporating the viruses, and methods of immunizing a human host by inoculation with the vaccines are also disclosed. The genomes of the
vii
recombinant viruses each comprise a mutant of the HSV-I genome from which a portion thereof responsible for neurovirulence yet nonessential for growth is deleted. A gene from the HSV-2 genome responsible for coding an immunityinducing glycoprotein is inserted in the mutant genome between the end points of deletion therein.
4859765 SYNTHETIC PEPTIDE SEQUENCES USEFUL IN BIOLOGICAL AND PHARMACEUTICAL APPLICATIONS AND METHODS OF MANUFACTURE John Nestor, John G Moffatt, Hardy Chan assigned to Syntex (U S A ) Inc The present invention relates to novel synthetic antigens, conjugates and antibodies based upon specific peptide sequences and the production thereof. More particularly, the invention relates to a polypeptide which is a determinant site of a protein, the polypeptide having from 8 to 20 amino acid residues, having an amino-terminal amino acid and a carboxyl-terminal amino acid, wherein the polypeptide includes: (a) a four amino acid sequence which corresponds to the four amino acid sequence of a beta-turn of the protein; (b) a sequence of two to eight amino acid residues attached to the amino terminal (H2N-) of the four amino acid sequence; and (c) a sequence of two to eight amino acid residues attached to the carboxyl terminal (-COOH) of the four amino acid sequence, wherein the amino acid residues of subparts (b) and (c) correspond to those attached to the amino terminal and the carboxyl terminal, respectively of the beta-turn of the protein, and the pharmaceutically acceptable salts of the polypeptide. The invention relates to a conjugate which comprises the polypeptide described above with a macromolecular carrier. The invention also relates to antibodies and the production thereof which are specific for the polypeptide or the conjugate of the peptide described above. The synthetic polypeptide sequences, peptide conjugates and antibodies thereof are useful as antigens in the production
sequences either directly or as a fusion protein with the product of a procaryotic gene. The resulting expression product is then either a fusion protein comprising two or more antigenic materials or a fusion protein comprising a part of a procaryotic protein and two or more antigenic materials. These fusion products are capable of eliciting the formation of multivalent antibodies which are cross-reactive with any and all of the native antigenic material. A vaccine is also described utilizing these fusion products.
4859583 CHEMILUMINESCENT IMMUNOCHEMICAL TECHNIQUE FOR LOW MOLECULAR WEIGHT ANTIGENS Michael Heller, Larry Morrison assigned to Amoco Corporation A sample device and method for assaying samples containing members of immunological pairs by chemiluminescence include a first chamber wherein antibody-conjugated reagent antigen labelled with a chemiluminescence moiety is displaced from the antibody by sample antigen. The labelled reagent antigen diffuses into a second chamber, wherein the chemiluminescence moiety reacts with cofactors to produce a light emission proportional to the amount of sample antigen present.
4859587 RECOMBINANT HERPES SIMPLEX VIRUSES, VACCINES AND METHODS Bernard Roizman assigned to Institut Merieux Recombinant herpes viruses useful as effective ingredients in vaccines against both virulent HSV-I and HSV-2 are disclosed. Methods of preparing the recombinant viruses, vaccines incorporating the viruses, and methods of immunizing a human host by inoculation with the vaccines are also disclosed. The genomes of the
vii
recombinant viruses each comprise a mutant of the HSV-I genome from which a portion thereof responsible for neurovirulence yet nonessential for growth is deleted. A gene from the HSV-2 genome responsible for coding an immunityinducing glycoprotein is inserted in the mutant genome between the end points of deletion therein.
4859765 SYNTHETIC PEPTIDE SEQUENCES USEFUL IN BIOLOGICAL AND PHARMACEUTICAL APPLICATIONS AND METHODS OF MANUFACTURE John Nestor, John G Moffatt, Hardy Chan assigned to Syntex (U S A ) Inc The present invention relates to novel synthetic antigens, conjugates and antibodies based upon specific peptide sequences and the production thereof. More particularly, the invention relates to a polypeptide which is a determinant site of a protein, the polypeptide having from 8 to 20 amino acid residues, having an amino-terminal amino acid and a carboxyl-terminal amino acid, wherein the polypeptide includes: (a) a four amino acid sequence which corresponds to the four amino acid sequence of a beta-turn of the protein; (b) a sequence of two to eight amino acid residues attached to the amino terminal (H2N-) of the four amino acid sequence; and (c) a sequence of two to eight amino acid residues attached to the carboxyl terminal (-COOH) of the four amino acid sequence, wherein the amino acid residues of subparts (b) and (c) correspond to those attached to the amino terminal and the carboxyl terminal, respectively of the beta-turn of the protein, and the pharmaceutically acceptable salts of the polypeptide. The invention relates to a conjugate which comprises the polypeptide described above with a macromolecular carrier. The invention also relates to antibodies and the production thereof which are specific for the polypeptide or the conjugate of the peptide described above. The synthetic polypeptide sequences, peptide conjugates and antibodies thereof are useful as antigens in the production